CUNY-Graduate School of Public Health: Opportunities and Challenges Following Approval of Resmetirom for MASH Liver Disease
April 25, 2024
April 25, 2024
NEW YORK, April 25 (TNSres) -- The City University of New York's Graduate School of Public Health and Health Policy issued the following news release:
Millions of people, and their doctors, have long wished for a pharmacological therapeutic for metabolic dysfunction-associated steatohepatitis (MASH), and the FDA's March 14 approval of resmetirom as the first drug to treat it represents a significant milestone. However, unless there are substantial changes in policy and better diseas . . .
Millions of people, and their doctors, have long wished for a pharmacological therapeutic for metabolic dysfunction-associated steatohepatitis (MASH), and the FDA's March 14 approval of resmetirom as the first drug to treat it represents a significant milestone. However, unless there are substantial changes in policy and better diseas . . .